Skip to main content

Autosomal Dominant Hypocalcemia clinical trials at UCSF

2 research studies open to eligible people

Autosomal dominant hypocalcemia is a rare condition that affects the body's calcium levels. UCSF is hosting a worldwide study to monitor people with this condition. Another trial is testing the safety and usefulness of a drug called encaleret.

Showing trials for
  • Encaleret Compared to Standard of Care in Participants With ADH1

    open to eligible people ages 16 years and up

    The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

    Oakland, California and other locations

  • ADH1 and ADH2 Disease Monitoring Study (DMS)

    open to eligible people ages up to 90 years

    A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

    Oakland, California and other locations

Last updated: